National Hispanic Heritage Month takes place from September 15 to October 15. We would like to honor this month by featuring some resources (from PRIM&R and from other organizations) that highlight the importance of the inclusion of the Latinx community in clinical research. Read more


We urge funders, study sponsors, researchers, ethicists, research leaders, accountants, and other stakeholders involved in decision-making regarding payments to Community Advisory Board (CAB) members to view CAB members as experiential experts whose time is valuable and whose contributions to science have long been undervalued. Valuing and paying CAB members can help operationalize trustworthiness, ethics, justice, equity, and fairness in the research process. The notion of CAB member involvement needs to be urgently reconsidered if we aim to work for full and representative inclusion and critical equity. Read more


In recognition of Pride Month, we'd like to highlight some resources—both from PRIM&R and from other organizations—that explore the importance of recognizing and including LGBTQIA+ people in research, strategies for reviewing LGBTQIA-specific research, and the unique ethical considerations for research with LGBTQIA+ populations (particularly children and youth). Read more


On April 14, 2022, the FDA released draft guidance that aims to diversify the population of participants in clinical trials. Because the guidance is a draft, its content is open for public discussion and comment. Earlier this week, PRIM&R submitted comment to the FDA explaining how the guidance, while welcome, might be improved. Comments are due June 13, 2022, and we encourage others to submit their own comments (and feel free to borrow from ours)! Read more


Diversity, equity, and inclusion have become a focal point since the COVID-19 pandemic exposed the disproportionate —and systemically ingrained— health disparities certain populations suffer from in the United States. IRBs have the difficult responsibility of both protecting participants from harm and ensuring the inclusion of underrepresented participants in research. Read more